CORONA vs SAKAR: Stock Comparison
Corona Remedies Ltd is the larger company by market capitalisation. Corona Remedies Ltd shows a higher ROE, a higher dividend yield and a higher ROCE, while Sakar Healthcare Limited shows a lower P/E, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
CORONA leads 5; SAKAR leads 8 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | CORONA | SAKAR |
|---|---|---|
| Sector | — | Healthcare |
| Industry | — | Pharmaceuticals |
Price
| Metric | CORONA | SAKAR |
|---|---|---|
| Live Price | ₹2,097.3 | ₹884.85 |
| Day Change | -2.41% | -1.63% |
| Volume | 14,193 | 77,175 |
| 52-Week High | ₹2,270.1 | ₹980 |
| 52-Week Low | ₹1,336.6 | ₹345.5 |
| Distance from 52W High | -7.61% | -9.71% |
Valuation
| Metric | CORONA | SAKAR |
|---|---|---|
| Market Cap | ₹12,843 Cr | ₹1,973 Cr |
| P/E Ratio | 66.01x | 56.29x |
| P/B Ratio | 17.59x | 6.26x |
| EPS | ₹30.3 | ₹13.68 |
| Book Value | ₹122 | ₹145.98 |
| Dividend Yield | 0.49% | 0% |
Growth
| Metric | CORONA | SAKAR |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 40.1% |
| EPS Growth (TTM YoY) | 0% | 87.2% |
| Qtr Sales Growth | 20.2% | 41.5% |
| Qtr Profit Growth | 43.7% | 91.3% |
Profitability & Leverage
| Metric | CORONA | SAKAR |
|---|---|---|
| ROE | 29.5% | 9.99% |
| ROCE | 33.3% | 12.7% |
| Net Margin | 13.19% | 12.11% |
| Operating Margin | 21% | 27.4% |
| Debt to Equity | 0.22x | 0.17x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | CORONA | SAKAR |
|---|---|---|
| Promoter Holding | 69% | 52.52%▼ 0.34 pp |
| FII Holding | 3.63%▲ 1.38 pp | 12.13%▼ 0.81 pp |
| DII Holding | 12.9%▲ 5.88 pp | 11.37%▲ 0.05 pp |
| Public Holding | 14.48%▼ 7.26 pp | 23.98%▲ 1.11 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Corona Remedies Ltd and Sakar Healthcare Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.